Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial.
about
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trialPersonalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients.Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants.'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase.Diseases Linked to Polypharmacy in Elderly Patients.Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges
P2860
Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Polypharmacy and major adverse ...... vations from the AFFIRM trial.
@en
type
label
Polypharmacy and major adverse ...... vations from the AFFIRM trial.
@en
prefLabel
Polypharmacy and major adverse ...... vations from the AFFIRM trial.
@en
P2860
P1476
Polypharmacy and major adverse ...... rvations from the AFFIRM trial
@en
P2093
Brian Olshansky
Gregory Y H Lip
P2860
P2888
P304
P356
10.1007/S00392-015-0936-Y
P577
2015-11-02T00:00:00Z